Since previous studies have revealed that PAK4 is involved in tumor cell infiltration by immune cells through regulation of WNT/β-catenin pathway, PAK4-targeted inhibitors may have synergic effect with PD-1/PD-L1 checkpoint blockades. Here, PAK4 is linked to neoplasm.